Dislipidemia y riesgo vascular. Una revisión basada en nuevas evidencias / Dyslipidaemia and vascular risk. A new evidence based review

La dislipidemia es uno de los principales factores de riesgo de cardiopatía isquémica, primera causa de mortalidad en el mundo. Realizar una detección temprana y una intervención terapéutica precoz son elementos clave a la hora de establecer una adecuada prevención de una enfermedad cardiovascular. Debemos conocer el arsenal terapéutico de que disponemos para su adecuada utilización en cada una de las situaciones clínicas que puedan presentar nuestros pacientes. En los últimos 3 años, la proliferación de múltiples guías para el manejo clínico del paciente dislipidémico con aparentes mensajes contradictorios en relación con la consecución de los objetivos de control llegan a confundir a los médicos. En esta revisión se pretende ofrecer una visión actualizada de la situación de la dislipidemia, partiendo del posicionamiento de las guías tanto europeas como americanas, pasando por diferentes situaciones de riesgo y finalizando con el concepto de dislipidemia aterogénica, reconocido factor de riesgo cardiovascular (AU)

Dyslipidaemia is one of the major risk factors for ischaemic heart disease, the leading cause of death worldwide. Early detection and therapeutic intervention are key elements in the adequate prevention of cardiovascular disease. It is essential to have knowledge of the therapeutic arsenal available for their appropriate use in each of the clinical situations that might be presented in our patients. In the past 3 years, there has been a proliferation of multiple guidelines for the clinical management of patients with dyslipidaemia, with apparent contradictory messages regarding the achievement of the control objectives, which are confusing clinicians. This review aims to provide an updated overview of the situation as regards dyslipidaemia, based on the positioning of both European and American guidelines, through different risk situations and ending with the concept of atherogenic dyslipidaemia as a recognized cardiovascular risk factor (AU)

[Dyslipidaemia and vascular risk. A new evidence based review]. / Dislipidemia y riesgo vascular. Una revisión basada en nuevas evidencias.

Dyslipidaemia is one of the major risk factors for ischaemic heart disease, the leading cause of death worldwide. Early detection and therapeutic intervention are key elements in the adequate prevention of cardiovascular disease. It is essential to have knowledge of the therapeutic arsenal available for their appropriate use in each of the clinical situations that might be presented in our patients. In the past 3 years, there has been a proliferation of multiple guidelines for the clinical management of patients with dyslipidaemia, with apparent contradictory messages regarding the achievement of the control objectives, which are confusing clinicians. This review aims to provide an updated overview of the situation as regards dyslipidaemia, based on the positioning of both European and American guidelines, through different risk situations and ending with the concept of atherogenic dyslipidaemia as a recognized cardiovascular risk factor.

[Dyspnea as the first clinical manifestation of amyloidosis]. / Disnea como primera manifestación clínica de amiloidosis.

We present a case of a 65-year-old woman, in whom diagnosis of primary systemic amyloidosis was established, being dyspnea the main cause of consultation. In addition, we emphasize the importance of the adequate valorization of such symptom in a patient with no precedents of cardiorespiratory pathology.

[Sweet's syndrome]. / Síndrome de Sweet.

A 42 year old female, diagnosed as having Sweet's syndrome, is presented as a new case of this rare disease (less than 100 cases reported before 1985) and the literature of the syndrome is reviewed. The clinical and histological features and its association with other diseases, especially the pathogenesis and treatment, are commented on.